US Federal House Bill HB1142

US Federal 2025-2026 Regular Session

• Introduced: 2/7/25
• Refer: 2/7/25

Caption

To amend the Public Health Service Act to direct the Secretary of Health and Human Services to establish drug adherence guidelines, and for other purposes.

Impact

The introduction of drug adherence guidelines is expected to bring significant changes to how Medicare beneficiaries manage their medications. By focusing on adherence, the bill aims to ensure that patients take their medications as prescribed, thereby reducing hospitalizations and other medical interventions due to poor medication compliance. The emphasis on using artificial intelligence and machine learning in developing these guidelines could lead to innovative solutions that tailor adherence strategies to individual patient needs.

Summary

House Bill 1142 seeks to amend the Public Health Service Act by directing the Secretary of Health and Human Services to establish drug adherence guidelines. The primary goal of these guidelines is to achieve a 90 percent adherence rate for all Medicare Part B and D drugs. This move aims to enhance the effectiveness of medication use among Medicare beneficiaries, ultimately improving health outcomes and reducing healthcare costs associated with non-adherence to prescribed drug regimens.

Contention

While the bill's supporters highlight the potential benefits of increased drug adherence, particularly in terms of healthcare outcomes, there may be concerns about the logistics and practicalities of implementing such guidelines. Issues such as provider adoption of new technologies, patient education, and access to generic or biosimilar drugs might pose challenges. Additionally, the requirement to promote generics may lead to discussions about the balance between pharmaceutical innovation and cost-control measures within the Medicare system.

Congress_id

119-HR-1142

Policy_area

Health

Introduced_date

2025-02-07